Nucleic Acid Testing: A Vehicle for Advancing Personalized Medicine

Published by	Decision Resources, Inc.
Published	April, 2009	Product code	86118
Content info	29 Pages
Price	US $ 3450 PDF by E-mail (Global License)

Introduction
Related Reports

Nucleic Acid Testing: A Vehicle for Advancing Personalized Medicine published by Decision Resources, Inc. in April, 2009. This report consists of 29 Pages and the price starts from US $ 3450.

Introduction

Abstract

Introduction

One of the fastest-growing segments of molecular diagnostics is nucleic acid testing (NAT). NAT is central to the life sciences industry, to improved healthcare, and to personalized medicine. Tools based on NAT are used to discover new biomarkers and develop in vitro diagnostics. Companies large and small are recognizing the value of NAT, and both R&D and dealmaking activity is robust. Find out who the players are and how they are vying for commercial success.

Get the Answers You Need to Shape Your Strategy

NAT is a leading molecular diagnostics technology. What are the advantages of NAT over other molecular diagnostics technologies? Which elements of NAT will drive personalized medicine forward?
Polymerase chain reaction (PCR) is one of the most common methods in the NAT toolbox used to discover new biomarkers and develop diagnostics tests. What other methods are commonly used for NAT? Which of these methods have the most product development activity?
Roche Diagnostics is the clear leader in molecular diagnostics. How do Roche' s sales fi gures compare with those of smaller diagnostics players? What does the competition look like within the smaller segments?
How are companies using dealmaking to advance their positions?
Infectious disease and oncology are the two main therapy areas for use of NAT technologies. What are the growth trends and growth drivers within these therapy areas? What companies are positioned to tap the opportunities?

Scope

Importance of NAT for advancing personalized medicine: Use of and rationale for NAT techniques and products to support the push for personalized medicine.
Key mergers and acquisitions (M&As), collaboration, and licensing activities in NAT: Two tables featuring 92 alliances that occurred from November 2007 through December 2008.

Executive Summary
- Strategic Considerations
- Stakeholder Implications
Introduction to NAT - A Central Technology
- Driving the Evolution to Personalized Medicine
- Affecting Drug Discovery and Approval
- Leading the Molecular Diagnostic Assay Technologies
- Scope of the Report
The NAT Toolbox: Technologies for Now and the Future
Therapeutic Focus of the NAT Market
- Blood Screening and Infectious Diseases
  - Testing for Sexually Transmitted Infections
  - Hospital-Acquired Infections Testing
  - HIV Drug Resistance Testing
  - Infectious Respiratory Diseases
- Oncology
  - Hereditary Risk Assays
  - Early Detection Assays
  - Targeted Therapy Assays
  - Assays for Cancer Prognosis
  - Assays Guiding Treatment Options
Company Leaders in NAT
Future Trends
- Applications That Will Drive the NAT Market for the Foreseeable Future
- Leading Companies in NAT Will Drive Growth Through Acquisitions and Licensing
- NAT Assays Are High Value, but Tests Need to Demonstrate Cost-Effectiveness

Sidebar

Using Discovery Tools to Shape Future NAT Oncology Assays

Tables

1. The Nucleic Acid Testing Toolbox
2. Validated Genomic Biomarkers for Select Approved Agents
3. Select Nucleic Acid Testing Leaders, by Market Segment
4. Select Acquisitions in NAT, November 2007-December 2008
Appendix A. Select Licensing and Collaboration Activities in NAT, November 2007-December 2008